> Detailanzeige

Georges, Jean-Louis; Gilles, Floriane; Cochet, Hélène; Bertrand, Alisson; De Tournemire, Marie; Monguillon, Victorien; Pasqualini, Maeva; Prevot, Alix; Roger, Guillaume; Saba, Joseph; Soltani, Joséphine; Koukabi-Fradelizi, Mehrsa; Beressi, Jean-Paul; Laureana, Cécile; Prost, Jean-François; Livarek, Bernard

Positive association of angiotensin II receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Positive association of angiotensin II receptor blockers, not angiotensin-converting enzyme inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia
  • Beteiligte: Georges, Jean-Louis; Gilles, Floriane; Cochet, Hélène; Bertrand, Alisson; De Tournemire, Marie; Monguillon, Victorien; Pasqualini, Maeva; Prevot, Alix; Roger, Guillaume; Saba, Joseph; Soltani, Joséphine; Koukabi-Fradelizi, Mehrsa; Beressi, Jean-Paul; Laureana, Cécile; Prost, Jean-François; Livarek, Bernard
  • Erschienen: Public Library of Science (PLoS), 2020
  • Erschienen in: PLOS ONE, 15 (2020) 12, Seite e0244349
  • Sprache: Englisch
  • DOI: 10.1371/journal.pone.0244349
  • ISSN: 1932-6203
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: BackgroundAngiotensin-converting enzyme 2 is the receptor that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses for entry into lung cells. Because ACE-2 may be modulated by angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), there is concern that patients treated with ACEIs and ARBs are at higher risk of coronavirus disease 2019 (COVID-19) pneumonia.AimThis study sought to analyze the association of COVID-19 pneumonia with previous treatment with ACEIs and ARBs.Materials and methodsWe retrospectively reviewed 684 consecutive patients hospitalized for suspected COVID-19 pneumonia and tested by polymerase chain reaction assay. Patients were split into two groups, according to whether (group 1, n = 484) or not (group 2, n = 250) COVID-19 was confirmed. Multivariable adjusted comparisons included a propensity score analysis.ResultsThe mean age was 63.6 ± 18.7 years, and 302 patients (44%) were female. Hypertension was present in 42.6% and 38.4% of patients in groups 1 and 2, respectively (P = 0.28). Treatment with ARBs was more frequent in group 1 than group 2 (20.7% vs. 12.0%, respectively; odds ratio [OR] 1.92, 95% confidence interval [CI] 1.23–2.98; P = 0.004). No difference was found for treatment with ACEIs (12.7% vs. 15.7%, respectively; OR 0.81, 95% CI 0.52–1.26; P = 0.35). Propensity score-matched multivariable logistic regression confirmed a significant association between COVID-19 and previous treatment with ARBs (adjusted OR 2.36, 95% CI 1.38–4.04; P = 0.002). Significant interaction between ARBs and ACEIs for the risk of COVID-19 was observed in patients aged > 60 years, women, and hypertensive patients.ConclusionsThis study suggests that ACEIs and ARBs are not similarly associated with COVID-19. In this retrospective series, patients with COVID-19 pneumonia more frequently had previous treatment with ARBs compared with patients without COVID-19.
  • Zugangsstatus: Freier Zugang